RecruitingPhase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

United States60 participantsStarted 2025-08-27

Plain-language summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer * Able to take oral medication * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements * Adequate organ function and electrolytes Key Exclusion Criteria: * Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812 * Impaired cardiac function * Major surgery within 28 days of the first dose of study drug

What they're measuring

Number of Participants with Dose-limiting Toxicities (DLTs)

Timeframe: Cycle 1 (28 days)

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Timeframe: Up to 42 months

Number of Participants With Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs

Timeframe: Up to 42 months

Trial details

NCT IDNCT06966024

SponsorDeciphera Pharmaceuticals, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-02

Contact for this trial

Clinical Team

888-724-3274 clinicaltrials@deciphera.com

View on ClinicalTrials.gov More Renal Cell Carcinoma trials